Maharashtra Hospitals Push for Revised Medical Device Pricing Framework as FDA Scrutinises Markup Rates

Hospitals in Maharashtra have urged the state food and drug administration to overhaul the existing pricing framework for medical devices, warning that a one-size-fits-all regulatory model is undermining both healthcare delivery and innovation. The plea comes after the Maharashtra FDA flagged concerning markup levels on certain medical equipment and consumables sold within the state.

Hospital administrators and healthcare industry representatives argue that the current pricing review mechanism does not distinguish between simple, high-volume consumables and sophisticated, low-volume technological equipment. Routine items such as syringes, gloves, and basic implants involve minimal procurement complexity but often carry outsized margins that warrant closer scrutiny. Meanwhile, advanced devices like robotic surgery systems, specialised imaging equipment, and high-end ventilators require substantial investments in training, maintenance, and certified clinical staff — costs that are currently not adequately reflected in pricing assessments.

The Maharashtra FDA has been conducting spot checks on device pricing across private healthcare facilities in recent months, identifying cases where markups on certain products significantly exceeded reasonable thresholds. In response, hospital groups have requested that the regulator adopt a tiered evaluation system. Under this proposed framework, routine consumables would face stricter margin caps, while complex technologies would be assessed on a case-by-case basis that factors in installation costs, recurring service contracts, and the expertise required for safe deployment.

Healthcare professionals stress that without such differentiation, hospitals may face financial pressure to either absorb losses on advanced treatments or restrict their availability — potentially harming patient access to cutting-edge care. The debate also touches on broader questions about transparency in healthcare pricing, as patients and policymakers alike have expressed concern over unexpected charges linked to device usage during procedures.

The Maharashtra FDA has acknowledged the representations and indicated that consultations with industry stakeholders are ongoing. A final decision on whether to restructure the pricing review process is expected in the coming months.